New Delhi, Jan. 6 -- Dear reader, as 2025, a year of global tumult and volatility, rolls by, Mint's reporters and columnists look around the corner on what is coming in 2026-to help you know what to expect and prepare for it. Tell us what you think at feedback@livemint.com.

In July 2025, Mumbai-headquartered Glenmark grabbed the spotlight when it signed what was one of the biggest out-licensing deals for an Indian drugmaker with Chicago-based Abbvie Inc. for an under-development cancer drug. The firm's US-based unit, Ichnos Glenmark Innovation, signed a $700 million exclusive licensing agreement for its drug candidate to treat a rare blood cancer.

"We were always resilient in how we approached innovation. I think that's what finally rew...